private:cynata
|
3666835
|
Dec 3rd, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Dec 3rd, 2020 09:47AM
|
Dec 3rd, 2020 09:47AM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Dec 2nd, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Dec 2nd, 2020 12:07PM
|
Dec 2nd, 2020 12:07PM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Dec 1st, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Dec 1st, 2020 10:42AM
|
Dec 1st, 2020 10:42AM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Nov 30th, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Nov 30th, 2020 12:46PM
|
Nov 30th, 2020 12:46PM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Nov 29th, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Nov 29th, 2020 05:45PM
|
Nov 29th, 2020 05:45PM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Nov 28th, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Nov 28th, 2020 01:38PM
|
Nov 28th, 2020 01:38PM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Nov 27th, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Nov 27th, 2020 09:58AM
|
Nov 27th, 2020 09:58AM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Nov 26th, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Nov 26th, 2020 10:59AM
|
Nov 26th, 2020 10:59AM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Nov 25th, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Nov 25th, 2020 01:56PM
|
Nov 25th, 2020 01:56PM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|
private:cynata
|
3666835
|
Nov 24th, 2020 12:00AM
|
Cynata Therapeutics
|
1.3K
|
8.00
|
Open
|
Biotechnology
|
Nov 24th, 2020 11:07AM
|
Nov 24th, 2020 11:07AM
|
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
|
Open
|
|
Open
|
Suite 1, 1233 High Street
|
Armadale
|
Victoria
|
AU
|
3143
|
|
Cynata
|
|
|